Nemolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL31RA |
| Clinical data | |
| Trade names | Nemluvio |
| Other names | CIM-331, CD14152, nemolizumab-ilto |
| License data |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Proteolytic enzymes |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
Nemolizumab, sold under the brand name Nemluvio, is a medication for the treatment of prurigo nodularis.[2] It is a monoclonal antibody that blocks the interleukin-31 receptor A.
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[3]
Nemolizumab was approved for medical use in the United States in August 2024.[4]
Medical uses
[edit]Nemolizumab is indicated for the treatment of adults with prurigo nodularis.
Society and culture
[edit]Names
[edit]Nemolizumab is the international nonproprietary name.[5]
References
[edit]- ^ "Nemluvio- nemolizumab-ilto injection, powder, lyophilized, for solution". DailyMed. 13 August 2024. Retrieved 5 September 2024.
- ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
- ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
- ^ "Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis" (Press release). Galderma. 13 August 2024. Retrieved 14 August 2024 – via Business Wire.
- ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
Further reading
[edit]- Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. PMID 37888917.
External links
[edit]- Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
- Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |